- Home
- AEVA vs TRVI Comparison
AEVA vs TRVI Comparison
Compare AEVA & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEVA
- TRVI
- Stock Information
- Founded
- AEVA 2019
- TRVI 2011
- Country
- AEVA United States
- TRVI United States
- Employees
- AEVA N/A
- TRVI N/A
- Industry
- AEVA Auto Parts:O.E.M.
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- AEVA Consumer Discretionary
- TRVI Health Care
- Exchange
- AEVA Nasdaq
- TRVI Nasdaq
- Market Cap
- AEVA 560.5M
- TRVI 629.8M
- IPO Year
- AEVA N/A
- TRVI 2019
- Fundamental
- Price
- AEVA $17.32
- TRVI $6.32
- Analyst Decision
- AEVA Buy
- TRVI Strong Buy
- Analyst Count
- AEVA 6
- TRVI 8
- Target Price
- AEVA $13.60
- TRVI $19.31
- AVG Volume (30 Days)
- AEVA 2.8M
- TRVI 1.3M
- Earning Date
- AEVA 05-14-2025
- TRVI 05-08-2025
- Dividend Yield
- AEVA N/A
- TRVI N/A
- EPS Growth
- AEVA N/A
- TRVI N/A
- EPS
- AEVA N/A
- TRVI N/A
- Revenue
- AEVA $10,326,000.00
- TRVI N/A
- Revenue This Year
- AEVA $80.29
- TRVI N/A
- Revenue Next Year
- AEVA $196.79
- TRVI N/A
- P/E Ratio
- AEVA N/A
- TRVI N/A
- Revenue Growth
- AEVA 95.90
- TRVI N/A
- 52 Week Low
- AEVA $2.20
- TRVI $2.30
- 52 Week High
- AEVA $18.74
- TRVI $7.48
- Technical
- Relative Strength Index (RSI)
- AEVA 68.05
- TRVI 49.48
- Support Level
- AEVA $13.74
- TRVI $6.08
- Resistance Level
- AEVA $18.69
- TRVI $6.47
- Average True Range (ATR)
- AEVA 1.90
- TRVI 0.45
- MACD
- AEVA 0.08
- TRVI -0.02
- Stochastic Oscillator
- AEVA 77.39
- TRVI 34.73
About AEVA Aeva Technologies Inc.
Aeva Technologies Inc through its Frequency Modulated Continuous Wave (FMCW) sensing technology, designs a 4D LiDAR-on-chip that, along with its proprietary software applications, has the potential to enable the adoption of LiDAR across broad applications from automated driving to consumer electronics, consumer health, industrial automation, and security application. The company operates in North America, EMEA, and Asia. The company derives the majority of its revenue from North America.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.